They reported that SMARCA2 expression was severely decreased (>50% of tumor cells were negative) in 42% (37/89) of GCs and deficient SMARCA2 expression was usually in tubular and papillary adenocarcinoma but not in signet-ring cell or mucinous carcinoma. Here, SMARCA2 is linked to neoplasm.